Self-assembled polysaccharide nanogels for nasal delivery of biopharmaceuticals

Mucosal Delivery of Biopharmaceuticals: Biology, Challenges and Strategies

Volumn 9781461495246, Issue , 2014, Pages 325-332

  Nochi, Tomonori ^a   Yuki, Yoshikazu ^b,c   Akiyoshi, Kazunari ^c,d   Kiyono, Hiroshi ^b,c  

^a TOHOKU UNIVERSITY   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Cholesteryl group bearing pullulan; Nanogels; Nasal; Pullulan; Vaccines

Indexed keywords

EID: 84930038830     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9524-6_13     Document Type: Chapter

References (33)

1. Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec. 2010;10(6):366-76.
2. Wagner V, Dullaart A, Bock AK, Zweck A the emerging nanomedicine landscape. Nat Biotechnol. 2006;24(10):1211-7.
3. Akiyoshi K, Kobayashi S, Shichibe S, Mix D, Baudys M, Kim SW, Sunamoto J. Selfassembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. J Control Release. 1998;54(3):313-20.
4. Akiyoshi K, Sasaki Y, Sunamoto J. Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B. Bioconjug Chem. 1999;10(3):321-4.
5. NomuraY, Ikeda M, Yamaguchi N, AoyamaY, Akiyoshi K. Protein refolding assisted by selfassembled nanogels as novel artificial molecular chaperone. FEBS Lett. 2003;553(3):271-6.
6. NomuraY, SasakiY, Takagi M, Narita T, AoyamaY, Akiyoshi K. Thermoresponsive controlled association of protein with a dynamic nanogel of hydrophobized polysaccharide and cyclodextrin: heat shock protein-like activity of artificial molecular chaperone. Biomacromolecules. 2005;6(1):447-52.
7. Ikeda K, Okada T, Sawada S, Akiyoshi K, Matsuzaki K. Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett. 2006;580(28-29):6587-95.
8. Boridy S, Takahashi H, Akiyoshi K, Maysinger D the binding of pullulan modified cholesteryl nanogels to Abeta oligomers and their suppression of cytotoxicity. Biomaterials. 2009;30(29):5583-91.
9. Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 2007;7:9.
10. Kageyama S, Kitano S, Hirayama M, Nagata Y, Imai H, Shiraishi T, Akiyoshi K, Scott AM, Murphy R, HoffmanEW, Old LJ, Katayama N, Shiku H. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci. 2008;99(3):601-7.
11. Kunisawa J, Nochi T, Kiyono H. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol. 2008;29(11):505-13.
12. Kiyono H, Fukuyama S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol. 2004;4(9):699-710.
13. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines. 2004;3(6): 643-54.
14. YukiY, Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines. 2009;8(8):1083-97.
15. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011;71(12): 1591-622.
16. Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses. 2011;5(6):389-97.
17. Ambrose CS, Walker RE, Connor EM. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis. 2006;17(4):206-12.
18. Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol. 1999;236:215-36.
19. Ryan EJ, McNeela E, Pizza M, Rappuoli R, L. O'Neill, Mills KH. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro-And antiinflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol. 2000;165(10):5750-9.
20. Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.Vaccine. 2008;26(37):4849-59.
21. Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol. 2003;13(5):293-310.
22. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004;350(9):896-903.
23. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun. 1998;66(10):4817-22.
24. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N, Tokuhara D, Kurokawa S, TakahashiY, Tsukada H, Kozaki S, Akiyoshi K, Kiyono H. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater. 2010;9(7):572-8.
25. Ayame H, Morimoto N, Akiyoshi K. Self-Assembled cationic nanogels for intracellular protein delivery. Bioconjug Chem. 2008;19(4):882-90.
26. YukiY, Nochi T, Harada N, KatakaiY, Shibata H, Mejima M, Kohda T, Tokuhara D, Kurokawa S, Takahashi Y, Ono F, Kozaki S, Terao K, Tsukada H, Kiyono H. In vivo molecular imaging analysis of a nasal vaccine that induces protective immunity against botulism in nonhuman primates. J Immunol. 2010;185(9):5436-43.
27. van Ginkel FW, Jackson RJ, YukiY, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol. 2000;165(9):4778-82.
28. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, Schilling M, Ferguson LM, Hollingshead SK, Briles DE, Becker RS. Immunization of healthy adults with a single recombinant pneumococcal surface proteinA (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine. 2000;18(17):1743-54.
29. Crain MJ, Waltman WD 2nd, Turner JS, Yother J, Talkington DF, McDaniel LS, Gray BM, Briles DE. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infecti Immun. 1990;58(10):3293-9.
30. Kong IG, Sato A, YukiY, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, Briles DE, Kunisawa J, InoueY, Yamamoto M, Akiyoshi K, Kiyono H. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infecti Immun. 2013;81(5):1625-34.
31. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, Thompson CM, Harney KF, Anderson PW, Lipsitch M, Malley R. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 2008;4(9):e1000159.
32. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4 + T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A. 2005;102(13):4848-53.
33. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345-50.